Medicine Press release



Eisai Contributes to the Science of Cancer Medicine at ASCO 2022
May 27, 2022 11:49 JST
Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO22), which is taking place virtually and in-person in Chicago from June 3 to 7.
More info..


Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS
May 27, 2022 11:24 JST
Eisai Co., Ltd. announced today that it has received orphan drug designation for ultrahigh-dose mecobalamin, with a prospective indication for delaying the progression of disease and functional impairment of amyotrophic lateral sclerosis (ALS), by the Ministry of Health, Labour and Welfare (MHLW).
More info..


Fujitsu and RIKEN start joint research on next-generation IT drug discovery technology using the supercomputer Fugaku and simulation integrated AI
May 17, 2022 10:32 JST
Fujitsu Limited and RIKEN today launched a joint research project on next-generation IT drug discovery technology utilizing the supercomputer Fugaku(1), aiming to accelerate DX (digital transformation) in drug discovery, explore promising new areas in this process, and dramatically reduce development period and costs for new drug development.
More info..


Hitachi High-Tech and Invivoscribe Partner to Advance Molecular Diagnostics
May 10, 2022 14:18 JST
Hitachi High-Tech Corporation has entered into a strategic partnership (the Partnership) with Invivoscribe, Inc., a global provider of blood cancer testing kits and services, by undertaking a minority investment-based, third-party allotment of shares.
More info..


Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway
May 10, 2022 10:23 JST
Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) under the accelerated approval pathway.
More info..


Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan
May 10, 2022 10:00 JST
Eisai Co., Ltd. today announced that it has initiated preparation on a New Drug Application for ultrahigh-dose mecobalamin.
More info..


Fujitsu and Southern Tohoku General Hospital start joint research on AI technology for detecting pancreatic cancer from non-contrast CT scans
Apr 25, 2022 13:37 JST
Fujitsu and the Southern Tohoku General Hospital today announced the launch of a joint research project with Fujitsu Japan Limited (hereinafter Fujitsu Japan) and FCOM CORPORATION (hereinafter FCOM) on an AI technology for the early detection of pancreatic cancer from computed tomography (CT) scans without contrast agent (non-contrast CT scans) starting April 1, 2022.
More info..


Shionogi and NEC Enter into Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine
Apr 18, 2022 15:03 JST
Shionogi & Co., Ltd. and NEC Corporation, today announced the execution of a strategic research collaboration agreement for the development of a novel hepatitis B therapeutic vaccine. NEC OncoImmunity, an NEC subsidiary that specializes in artificial intelligence-driven biotechnology, is also participating in this research collaboration.
More info..


Shionogi and NEC Enter into Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine
Apr 18, 2022 15:03 JST
Shionogi & Co., Ltd. and NEC Corporation, today announced the execution of a strategic research collaboration agreement for the development of a novel hepatitis B therapeutic vaccine. NEC OncoImmunity, an NEC subsidiary that specializes in artificial intelligence-driven biotechnology, is also participating in this research collaboration.
More info..


CEPI Partners with Japan's NEC Group to Develop Artificial Intelligence-designed Broadly Protective Betacoronavirus Vaccine
Apr 08, 2022 13:50 JST
CEPI, the Coalition for Epidemic Preparedness Innovations, and NEC Corporation (NEC: TSE: 6701) today announced the latest funding award under its US$200m programme to advance the development of vaccines that provide broad protection against SARS-CoV-2 variants and other betacoronaviruses.
More info..